SEC Comment Letter 0000000000-24-014261 to CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERO THERAPEUTICS HOLDINGS, INC.
Date: Dec. 26, 2024 · CIK: 0001870404 · Accession: 0000000000-24-014261
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284007
Letter
December 26, 2024 Chris Ehrlich Chief Executive Officer CERo Therapeutics Holdings, Inc. 201 Haskins Way, Suite 230 South San Francisco, CA 94080 Re:CERo Therapeutics Holdings, Inc. Registration Statement on Form S-1 Filed December 23, 2024 File No. 333-284007 Dear Chris Ehrlich: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeffrey A. Letalien
Show Raw Text
December 26, 2024
Chris Ehrlich
Chief Executive Officer
CERo Therapeutics Holdings, Inc.
201 Haskins Way, Suite 230
South San Francisco, CA 94080
Re:CERo Therapeutics Holdings, Inc.
Registration Statement on Form S-1
Filed December 23, 2024
File No. 333-284007
Dear Chris Ehrlich:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeffrey A. Letalien